Shopping Cart
Remove All
Your shopping cart is currently empty
Xentuzumab
(Synonyms: BI 836845) Copy Product Info
🥰Excellent
Synonyms: BI 836845
Catalog No. T76795 Copy Product Info
Purity: 95.21%
🥰Excellent
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
Cas No. 1417158-65-6
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $347 | In Stock | In Stock | |
| 5 mg | $886 | In Stock | In Stock | |
| 10 mg | $1,450 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.21%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. |
| In vitro | After 5 or 10 days of incubation, single-agent Xentuzumab(XENT)or ENZA reduced the viability of VCaP, DuCaP, and MDA PCa 2b cells in a dose-dependent manner. Combination therapy further decreased cell viability compared to monotherapy; likewise, treatment with XENT+ENZA resulted in a significant reduction in the expression of cell cycle genes, ubiquitin-conjugating enzyme E2 C (UBE2C), cyclin-dependent kinase 1 (CDK1), and cell division cycle protein 20 (CDC20) compared to single-agent treatment.[1]. |
| In vivo | Monotherapy with ENZA did not inhibit tumor growth. However, the addition of Xentuzumab(XENT)rendered the tumors sensitive to ENZA again, leading to a significant reduction in tumor volume[1]. |
| Expression System | CHO |
| Endotoxin | <1.0 EU/mg |
| Synonyms | BI 836845 |
| Reactivity | Human |
| Verified Activity | Immobilized Human IGF1/IGF-I Protein (TMPY-06982) at 1 μg/mL (100 μL/well) can bind Xentuzumab. The EC50 is 12.86 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IGF-1 |
| Molecular Weight | 143.7 kDa |
| Cas No. | 1417158-65-6 |
| Isotype | Human IgG1 lambda C2 |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Xentuzumab chemical structure | Xentuzumab in vivo | Xentuzumab in vitro | Xentuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.